Katherine Clifton - Concepedia

Author

Katherine Clifton

Washington University in St. Louis ORCID

Also Known As

K. Clifton, K.K. Clifton, Katherine Clifton, Katherine K Clifton, Katherine K. Clifton, Katherine Keaney Clifton

204

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis The University of Texas MD Anderson Cancer Center Guardant (United States)Massachusetts General Hospital Northwestern University

About

Katherine Clifton is an author at Washington University in St. Louis specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	304
2	Geriatrics	2	2	212
3	Pathology	2	2	66
4	Health Sciences	1	1	26
5	Immunology	1	1	35

Katherine Clifton

Publications

886

Citations

H-Index

Page 1

	Year	Citations
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge Christine M. Parseghian, Jonathan M. Loree, Van K. Morris, Annals of Oncology	2018	228
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021 Efrat Dotan, Louise C. Walter, Ilene Browner, Journal of the National Comprehensive Cancer Network Palliative CareNccn Guidelines® InsightsGeriatric OncologyGeriatricsMedicine	2021	179
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases Amanda Parkes, Carla L. Warneke, Katherine Clifton, The Oncologist	2018	65
Characterization of bone only metastasis patients with respect to tumor subtypes Amanda Parkes, Katherine Clifton, Aydah Al‐Awadhi, npj Breast Cancer	2018	63
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Clinical Cancer Research	2023	44
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay Katherine Clifton, Thereasa A. Rich, Christine M. Parseghian, JCO Precision Oncology	2019	43
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer Foluso O. Ademuyiwa, Ina Chen, Jingqin Luo, Breast Cancer Research and Treatment Breast OncologyMedicineImmunologyPathologyCancer Genomics	2021	35
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population Katherine Clifton, Min Yi, Jaime Kimmel, Breast Cancer Research and Treatment Lifespan ExtensionProgression-free SurvivalGeriatricsLongevityMedicine	2019	33
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations Katherine Clifton, Angelica M. Gutierrez‐Barrera, Junsheng Ma, Breast Cancer Research and Treatment Surgical OncologyBreast OncologyMedicinePathologyBreast Cancer	2018	31
Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer William R. Kennedy, Maria A. Thomas, Jennifer Stanley, International Journal of Radiation OncologyBiologyPhysics Breast OncologyRadiation TherapyMedicineSingle-institution Phase 1/2Breast Imaging	2020	26

Page 1